Parul Doshi

2.9k citations

49 papers · 1.6k indexed · h-index 19

Co-authors: Joseph D. Szustakowski Radu Dobrin Alice M. Walsh Simon Papillon‐Cavanagh Maria Aguad Richard M. Kaufman Claudia I. Chapuy Paul W.H.I. Parren
Topics: Multiple Myeloma Research and Treatments (15 papers)Chronic Lymphocytic Leukemia Research (13 papers)Monoclonal and Polyclonal Antibodies Research (9 papers)
Cited by: Hematology Physiology Oncology
Journals: Journal of Clinical Oncology Blood Cancer Research
Partner nations: United States Netherlands Spain

In The Last Decade

Parul Doshi

47 papers receiving 1.6k citations

Peers

Countries citing papers authored by Parul Doshi

Since Specialization

Citations

This map shows the geographic impact of Parul Doshi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Parul Doshi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Parul Doshi more than expected).

Fields of papers citing papers by Parul Doshi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Parul Doshi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Parul Doshi. The network helps show where Parul Doshi may publish in the future.

Co-authorship network of co-authors of Parul Doshi

This figure shows the co-authorship network connecting the top 25 collaborators of Parul Doshi. A scholar is included among the top collaborators of Parul Doshi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Parul Doshi. Parul Doshi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Evaluation of tissue- and plasma-derived tumor mutational burden (TMB) and genomic alterations of interest in CheckMate 848, a study of nivolumab combined with ipilimumab and nivolumab alone in patients with advanced or metastatic solid tumors with high TMB 2023 ·Journal for ImmunoTherapy of Cancer ·Jie He,Natallia Kalinava,Parul Doshi,Dean C. Pavlick,Lee A. Albacker,Ericka M. Ebot,(unknown),James Pratt,Gina Fusaro,Geoffrey R. Oxnard,George Green,(unknown),Jonathan Baden	14
2	STK11 and KEAP1 mutations as prognostic biomarkers in an observational real-world lung adenocarcinoma cohort 2020 ·ESMO Open ·Simon Papillon‐Cavanagh,Parul Doshi,Radu Dobrin,Joseph D. Szustakowski,Alice M. Walsh	142
3	Daratumumab displays in vitro and in vivo anti-tumor activity in models of B-cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens 2019 ·Haematologica ·(unknown),Alba Matas‐Céspedes,Vanina Rodríguez,Cédric Rossi,Juan García Valero,Neus Serrat,Alejandra Sanjuán-Pla,Pablo Menéndez,Gaël Roué,Armando López‐Guillermo,Eva Giné,Elı́as Campo,Dolors Colomer,Christine Bezombes,Jeroen Lammerts van Bueren,Christopher Chiu,Parul Doshi,Patricia Pérez‐Galán	32
4	Mammary tumor-derived CCL2 enhances pro-metastatic systemic inflammation through upregulation of IL1β in tumor-associated macrophages 2017 ·OncoImmunology ·Kelly Kersten,Seth B. Coffelt,Marlous Hoogstraat,Niels J. M. Verstegen,Kim Vrijland,Metamia Ciampricotti,Chris W. Doornebal,Cheei‐Sing Hau,Max D. Wellenstein,Camilla Salvagno,Parul Doshi,Esther H. Lips,Lodewyk F.A. Wessels,Karin E. de Visser	85
5	Daratumumab in Combination with Carfilzomib and Dexamethasone in Patients (pts) with Relapsed Multiple Myeloma (MMY1001): An Open-Label, Phase 1b Study 2017 ·Blood ·Sagar Lonial,Jesús F. San Miguel,Joaquín Martínez‐López,María‐Victoria Mateos,Joan Bladé,Lotfi Benboubker,Albert Oriol,Bertrand Arnulf,Ajai Chari,Luis Piñeiro,Kaida Wu,Jianping Wang,Parul Doshi,Jordan M. Schecter,Philippe Moreau	9
6	Daratumumab (DARA) in Combination with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) in Patients with Newly Diagnosed Multiple Myeloma (MMY1001): Updated Results from an Open-Label, Phase 1b Study 2017 ·Blood ·Ajai Chari,Saad Z. Usmani,Amrita Krishnan,Sagar Lonial,Raymond L. Comenzo,Kaida Wu,Jianping Wang,Parul Doshi,Brendan M. Weiss,Jordan M. Schecter,Andrzej Jakubowiak	23
7	Split dosing of daratumumab (D) in a phase 1b study of D plus carfilzomib (K)-based regimens in patients (pts) with multiple myeloma (MM) 2017 ·Annals of Oncology ·Saad Z. Usmani,Andrzej Jakubowiak,Ajai Chari,Sagar Lonial,MV Mateos,Lotfi Benboubker,Kang Wu,Nushmia Z. Khokhar,(unknown),Parul Doshi,Philippe Moreau	6
8	Blood Transfusion Management and Transfusion-Related Outcomes in Daratumumab-Treated Patients With Relapsed or Refractory Multiple Myeloma 2017 ·Clinical Lymphoma Myeloma & Leukemia ·Ajai Chari,Suzanne Arinsburg,Sundar Jagannath,(unknown),(unknown),(unknown),Gareth J. Morgan,Huaibao Feng,Clarissa Uhlar,Imran Khan,Parul Doshi,Saad Z. Usmani	26
9	The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia–Microenvironment Interactions in Chronic Lymphocytic Leukemia 2016 ·Clinical Cancer Research ·Alba Matas‐Céspedes,(unknown),Vanina Rodríguez,Neus Villamor,Julio Delgado,Eva Giné,Heleia Roca-Ho,Pablo Menéndez,Elı́as Campo,Armando López‐Guillermo,Dolors Colomer,Gaël Roué,Adrian Wiestner,Paul W.H.I. Parren,Parul Doshi,Jeroen Lammerts van Bueren,Patricia Pérez‐Galán	45
10	Abstract A20: Mammary tumor-derived CCL2 enhances pro-metastatic systemic inflammation through upregulation of macrophage-derived IL1beta 2016 ·Cancer Research ·Kelly Kersten,Seth B. Coffelt,Niels J. M. Verstegen,Kim Vrijland,Metamia Ciampricotti,Chris W. Doornebal,Cheei‐Sing Hau,Parul Doshi,Karin E. de Visser	4
11	Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab 2015 ·Leukemia ·Inger S. Nijhof,Richard W.J. Groen,H M Lokhorst,Berris van Kessel,A C Bloem,(unknown),(unknown),Huipin Yuan,Willy A. Noort,Saskia K. Klein,Anton C. Martens,Parul Doshi,(unknown),Tuna Mutis,Niels W.C.J. van de Donk	203
12	Pre-clinical translational studies of daratumumab in patients with myeloma or AL amyloidosis undergoing autologous hematopoietic stem cell transplantation (SCT). 2015 ·Journal of Clinical Oncology ·Chakra P. Chaulagain,Xun Ma,Parul Doshi,Sandy W. Wong,Andreas K. Klein,Kellie Sprague,Ping Zhou,Ray Comenzo	2
13	Antitumor Efficacy of the Anti-Interleukin-6 (IL-6) Antibody Siltuximab in Mouse Xenograft Models of Lung Cancer 2014 ·Journal of Thoracic Oncology ·Lanxi Song,Matthew A. Smith,Parul Doshi,Kate Sasser,William J. Fulp,Soner Altiok,Eric B. Haura	85
14	Enhancement of paclitaxel and carboplatin therapies by CCL2 blockade in ovarian cancers 2014 ·Molecular Oncology ·(unknown),(unknown),Anamaria Brozović,George E. Durán,Yan C. Wang,Shalini Chaturvedi,Shobha Seetharam,Linda A. Snyder,Parul Doshi,Branimir I. Šikić	97
15	CNTO 95, a fully human anti αv integrin antibody, inhibits cell signaling, migration, invasion, and spontaneous metastasis of human breast cancer cells 2007 ·Clinical & Experimental Metastasis ·Qiming Chen,Carol D. Manning,Hillary J. Millar,Francis L. McCabe,(unknown),Celia Sharp,(unknown),Parul Doshi,Marian T. Nakada,Geoffrey M. Anderson	77
16	Extracellular signal-regulated kinase and p38 mitogen-activated protein kinase pathways cooperate in mediating cytokine-induced proliferation of a leukemic cell line 2002 ·Leukemia ·Sreesha P. Srinivasa,Parul Doshi	38
17	Enhanced ability of daniplestim and myelopoietin-1 to suppress apoptosis in human hematopoietic cells 2001 ·Leukemia ·James A. McCubrey,William L. Blalock,(unknown),M Pearce,Carla Burrows,LS Steelman,JT Lee,Richard A. Franklin,Stephanie M. Oberhaus,(unknown),Parul Doshi,(unknown)	9
18	Promegapoietin, a family of chimeric growth factors, supports megakaryocyte development through activation of IL-3 and c-Mpl ligand signaling pathways 2001 ·Experimental Hematology ·Parul Doshi,Judith G. Giri,Ann L. Abegg,(unknown),(unknown),Larry E. Kahn,John C. Minnerly,Lyle E. Pegg,Doreen Villani-Price,Ned R. Siegel,Nicholas R. Staten,John W. Thomas,John P. McKearn,Walter G. Smith	12
19	Population genetics of tandem repeats in centromeric heterochromatin: unequal crossing over and chromosomal divergence at the Responder locus of Drosophila melanogaster. 1993 ·Genetics ·Eric L. Cabot,Parul Doshi,Mark Li‐cheng Wu,Chung‐I Wu	34
20	Two α-tubulin genes of Aspergillus nidulans encode divergent proteins 1991 ·Molecular and General Genetics MGG ·Parul Doshi,Cynthia A. Bossie,John H. Doonan,(unknown),N. Ronald Morris	36

About Parul Doshi

Parul Doshi is a scholar working on Hematology, Genetics and Immunology, having authored 49 papers that have together received 1.6k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (15 papers), Chronic Lymphocytic Leukemia Research (13 papers) and Monoclonal and Polyclonal Antibodies Research (9 papers). The work is most often cited by research in Hematology (745 citations), Physiology (136 citations) and Oncology (787 citations). Parul Doshi has collaborated with scholars based in United States, Netherlands and Spain. Frequent co-authors include Joseph D. Szustakowski, Radu Dobrin, Alice M. Walsh, Simon Papillon‐Cavanagh, Maria Aguad, Richard M. Kaufman, Claudia I. Chapuy, Paul W.H.I. Parren, Kate Sasser and Paul G. Richardson. Their work appears in journals such as Journal of Clinical Oncology, Blood and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact